Clinical Trials Directory

Trials / Completed

CompletedNCT05511740

Circadian as A Prognostic Factor For Radiation Response in Cervical Cancer

Influence of Radiation Patterns Following Circadian Rhythm Upon Response of Radiotherapy of Uterine Cervical Cancer : Melatonin as a Radiosensitivity and Biological Marker

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
71 (actual)
Sponsor
Indonesia University · Academic / Other
Sex
All
Age
25 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The study was a Randomized Clinical Trial (RCT) or clinical trial comparing the results of radiation treatment of 2 treatment groups, i.e. subject groups irradiated in the morning and in the afternoon, to check melatonin levels in cervical cancer patients. Since it is known that the function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.

Conditions

Interventions

TypeNameDescription
RADIATIONAfternoon RadiationMelatonin, a hormone of the pineal gland, which levels are characteristic of circadian patterns, regulated with low levels of excretion in the afternoon, rises gradually during the night, peaks at dawn, and falls back in the afternoon and late afternoon. Many studies prove the function and potential of melatonin as circadian biomarkers and well correlated with the development of cancer.The function of melatonin is as an antiproliferation substance or hormone, induces apoptosis, inhibits invasion and metastasis.

Timeline

Start date
2010-01-01
Primary completion
2014-07-01
Completion
2014-07-01
First posted
2022-08-23
Last updated
2022-08-23

Source: ClinicalTrials.gov record NCT05511740. Inclusion in this directory is not an endorsement.